Simpirica Spine is a technology company.
Simpirica Spine has raised $22.0M across 1 funding round.
Key people at Simpirica Spine.
Simpirica Spine has raised $22.0M in total across 1 funding round.
Simpirica Spine has raised $22.0M in total across 1 funding round.
Simpirica Spine's investors include Norwest Venture Partners.
Key people at Simpirica Spine.
Simpirica Spine is a medical device company developing minimally invasive spinal stabilization solutions as alternatives to traditional spinal fusion.[1][2][3] Its flagship product, the LimiFlex Dynamic Sagittal Tether, restores natural segmental motion and stability post-lumbar decompression for patients with degenerative spondylolisthesis and spinal stenosis, serving spine surgeons and patients in the healthcare sector.[1] The company, based in San Carlos, California, has raised $27M in funding, with the last round ($5M) occurring 11 years ago, and remains in a debt stage while alive per recent records.[1][5] It targets chronic spinal conditions, offering flexion-restricting devices to improve rehabilitation and function without fusion.[2][3][6]
Founded in 2006, Simpirica Spine emerged to address unmet needs in spinal stabilization through minimally invasive, flexion-restricting devices.[1][2][3][5] Specific founders are not detailed in available records, but the company quickly advanced its lead product, securing a $22M Series C round led by Norwest Venture Partners to support development and trials.[3] Early traction included closing this funding outside the U.S. for product maturation, positioning it as a fusion alternative via its Spinal Stabilization System.[2][3][4] Headquartered at 1680 Bayport Ave in San Carlos, it grew to focus on devices like LimiFlex amid a competitive medtech landscape.[1][5]
Simpirica Spine rides the trend toward motion-preserving spinal technologies, driven by rising demand for less invasive orthopedics amid aging populations and chronic back pain epidemics.[1][2] Timing aligns with advances in biomaterials and imaging, enabling precise tether deployment over rigid fusion, which dominates but faces scrutiny for high reoperation rates.[4][6] Market forces like healthcare cost pressures favor alternatives reducing recovery time and complications, influencing ecosystems by challenging incumbents (e.g., Spinal Elements, Simplify Medical) and inspiring hybrid devices.[1][5] It contributes to a shift toward dynamic stabilization, potentially expanding medtech portfolios for investors eyeing $10B+ spine markets.
Simpirica Spine's low employee count (2 as of recent data) and stagnant funding since ~2014 suggest a holding pattern, possibly awaiting regulatory milestones or partnerships for LimiFlex commercialization.[1][5] Next steps likely involve U.S. FDA clearance pushes or acquisitions by larger medtech firms, capitalizing on post-pandemic spine procedure rebounds. Trends like AI-guided implants and biologics integration could amplify its tether tech, evolving its role from niche innovator to ecosystem enabler—echoing its founding promise of fusion alternatives in a maturing motion-preservation wave.[1][2]
Simpirica Spine has raised $22.0M across 1 funding round. Most recently, it raised $22.0M Series C in September 2011.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Sep 1, 2011 | $22.0M Series C | Norwest Venture Partners |
